Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shoji Takakura
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Nilvadipine, a New Calcium Channel Blocker, Reduces Ischemic Brain Injury in Rats.
The Japanese Journal of Pharmacology
Related publications
Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Drugs in Context
Molecular Medicine
Pharmacology
Effects of Rifampin, Cyclosporine A, and Probenecid on the Pharmacokinetic Profile of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Healthy Participants
International Journal of Clinical Pharmacology and Therapeutics
Pharmacology
Protective Effects of Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on a Non-Alcoholic Steatohepatitis Mouse Model
Yonago Acta Medica
Medicine
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally
US Endocrinology
Endocrinology
Metabolism
Diabetes
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin
Pharmaceutics
Pharmaceutical Science
The Long-Term Efficacy of Sodium Glucose Co-Transporter 2 Inhibitor in Patients With Non-Alcoholic Fatty Liver Disease
Internal Medicine
Internal Medicine
Medicine
Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis
Retrospective Analysis of Effects of Sodium-Glucose Co-Transporter 2 Inhibitor in Japanese Type 2 Diabetes Mellitus Patients With Chronic Kidney Disease
Diabetes and Vascular Disease Research
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through?
Anaesthesia
Anesthesiology
Pain Medicine
